Condition
Metastatic Digestive System Neuroendocrine Neoplasm
Total Trials
4
Recruiting
1
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Active Not Recruiting3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT03375320Phase 3Active Not Recruiting
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT04234568Phase 1Active Not RecruitingPrimary
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
NCT03891784Phase 2Active Not Recruiting
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
NCT06016855Phase 4Recruiting
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Showing all 4 trials